1. Home
  2. AMST vs GRDX Comparison

AMST vs GRDX Comparison

Compare AMST & GRDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Amesite Inc.

AMST

Amesite Inc.

HOLD

Current Price

$1.33

Market Cap

8.2M

Sector

Technology

ML Signal

HOLD

Logo GridAI Technologies Corp.

GRDX

GridAI Technologies Corp.

N/A

Current Price

$2.55

Market Cap

7.3M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
AMST
GRDX
Founded
2017
N/A
Country
United States
United Kingdom
Employees
N/A
2
Industry
Computer Software: Prepackaged Software
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
8.2M
7.3M
IPO Year
2020
N/A

Fundamental Metrics

Financial Performance
Metric
AMST
GRDX
Price
$1.33
$2.55
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
14.6K
93.5K
Earning Date
05-14-2026
05-14-2026
Dividend Yield
N/A
N/A
EPS Growth
40.46
N/A
EPS
N/A
N/A
Revenue
$110,459.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.57
$1.87
52 Week High
$4.78
$5.30

Technical Indicators

Market Signals
Indicator
AMST
GRDX
Relative Strength Index (RSI) 27.04 52.60
Support Level N/A $1.99
Resistance Level $1.92 $2.68
Average True Range (ATR) 0.10 0.28
MACD -0.02 0.08
Stochastic Oscillator 6.71 48.89

Price Performance

Historical Comparison
AMST
GRDX

About AMST Amesite Inc.

Amesite Inc is an artificial intelligence-driven platform and course designer that rapidly provides customized, high-performance and scalable online products for schools and businesses. The company helps educational institutions and businesses improve learning as their technology partner, delivering a disruptive technology driven by AI and offers a constellation of services that help partners implement new programs, and improve existing ones. Its customers are Enterprises, universities, and K-12 schools.

About GRDX GridAI Technologies Corp.

GridAI Technologies Corp, formerly known as Entero Therapeutics Inc, is a late clinical-stage biopharmaceutical company focused on the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases. The company's programs address unmet needs in GI health and include: latiglutenase, a Phase 3-ready, potentially first-in-class, targeted, oral biotherapeutic for celiac disease; capeserod, a selective 5-HT4 receptor partial agonist for indications including gastroparesis; and adrulipase, a recombinant lipase enzyme designed to enable the digestion of fats and other nutrients in cystic fibrosis and chronic pancreatitis patients with exocrine pancreatic insufficiency.

Share on Social Networks: